Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut feeling: diet trial targets ADHD symptoms through Gut-Brain link

NCT ID NCT07376746

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests if a diet rich in fiber and fermented foods can reduce core ADHD symptoms in adults aged 18-50. Two hundred participants will be randomly assigned to either this special diet or standard healthy eating advice for 12 weeks. Researchers will track changes in symptoms, mood, thinking skills, and gut health to see if diet can ease ADHD.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

ADHD Group Inclusion Criteria: 1. Be able to give written informed consent 2. Should be stable for 4 weeks on psychopharmacological medication or without medication 3. Should have an established diagnosis of ADHD or ADD as the main mental disorder diagnosis. This will be validated by the ADHD diagnostic criteria after DSM-5, with the DIVA interview. 4. Aged 18-50 years 5. Fluency in English language Control Group Inclusion Criteria 1. Be able to give written informed consent 2. Should be stable for 4 weeks on any medication for physical health or without medication 3. Should not currently taking psychopharmacological medicine or discontinued psychopharmacological medicine in the past 6 months (due to relapse risk) 4. Should NOT have an established diagnosis or clinical symptoms of ADHD or ADD. This will be validated using with the ASRS-6 (\< 4) 5. Should not have a diagnosis of ASD as indicated by self-report. 6. Not have current, or in the past 2 years, symptoms or diagnosis of a depressive disorder, bipolar spectrum disorder, OCD, PTSD, generalised anxiety disorder, severe alcohol or illegal drug dependency, psychotic disorder, anorexia nervosa, and bulimia nervosa 7. Not have current symptoms or diagnosis of a panic disorder or social anxiety disorder that is not currently being treated by a psychotherapist or other mental health care professional 8. Aged 18-50 years 9. Fluency in English language ADHD and Control Group Exclusion criteria: 1. Current severe depressive (PHQ-9\>15), manic or psychotic episode, acute suicidality or suicide attempt in the past 3 months, current severe alcohol and illegal drug dependency as determined by the MINI Psychiatric Interview or clinical diagnosis. 2. Pregnant, breastfeeding, or planning to be pregnant. 3. Habitual fibre intake exceeding 25g/day. 4. Allergy to intervention foods. 5. Allergy to local anaesthesia (only if opting for the skin punch). 6. Taking anticoagulant medication or have coagulation disorder like haemophilia (only if opting for the skin punch). 7. Have a BMI below 18.5 kg/m2. 8. Current diagnosis or symptoms of anorexia nervosa or bulimia nervosa, as determined by clinical diagnosis or on the MINI. 9. Have a significant acute or chronic coexisting illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic) or any condition which contraindicates, in the investigator's judgement, entry to the study. 10. Taking antibiotics in the past month (washout period of 1 month is required). 11. Taking medication that the investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results; to include anti-inflammatory drugs, corticosteroids, laxatives, enemas, anti-coagulants, and over-the counter non-steroidal analgesics. Participants should have a wash-out period of one month. 12. Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the trial. 13. Participants receiving treatment involving experimental drugs. Washout period of one month is required. 14. Current prebiotic or probiotic supplement use (a wash-out period of 4 weeks after cessation will allow entry to the study). 15. Previous participation in the Diet Study (APC150) 16. Uncorrected vision. 17. A history of any other condition affecting cognitive function (besides ADHD or ASD for ADHD group participants). The specific exclusion criteria for electroencephalography (EEG) recording for both the ADHD and Control groups are as follows: 1. Left-handedness, 2. Non-removable medical devices such as pacemakers, hearing aids, cochlear implants, or deep brain stimulators, 3. Hairstyles that prevent access to the scalp, and 4. Skin conditions on the scalp. Participants who meet these exclusion criteria for the EEG portion of the study will still be included in the overall study but will not undergo EEG recording and will instead complete neurocognitive tasks outside of EEG recording.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APC Microbiome Ireland

    Cork, Cork, T12 YT20, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.